Author Archives: Megan Thomas

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

Human liver
#Drug delivery #Drug discovery #Liver disease

FDA Fast Track designation for liver disease treatment

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US… Read More

#News #Trending News

#Biologics / Biotechnology #Biomedicine #Drug discovery #Imaging #PET technology #Radiochemistry

MDC relaunches Wolfson radiochemistry facility

Medicines Discovery Catapult (MDC) has relaunched radiochemistry at the Wolfson Molecular Imaging Centre (WMIC) at the University of Manchester, UK. The facility, which was closed in 2020, includes the multi-million pound ‘Cyclotron’, one of only a few in the UK. It will supply radio-chemicals to drug discovery biotechs and academics,… Read More

#News

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing services. Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

#Drug design #Immunology / Virology & Vaccines #Lipidomics #Lipids #Metabolomics

Lipidomics in biomedical research: chance and challenges

Listen to this article on the DDW Podcast: Lipids are essential for numerous functions in the human body. They are not only components of cell membranes, extracellular vesicles and hormones, but also store energy, facilitate metabolism, mediate cell signalling pathways, and much more. Afrisha Anderson, a Product Manager at Merck KGaA,… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Diabetes #Research #Type 2 diabetes

Preclinical data on oral polymer-based duodenal exclusion therapy

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

Insilico Medicine discovers preclinical candidate for kidney fibrosis using AI

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to… Read More

#News

Cancer research
#Cancer #Cancer research #Cell therapy #Clinical trials #Oncology

The personal touch: the scientist making an impact in cancer research

Listen to this article on the DDW Podcast: At 33, Martyn Hiscox is an inspiration to scientists in oncology research. Principal scientist with Adaptimmune, a UK cell therapy biotech, Lu Rahman uncovers Hiscox’s passion, dedication and the personal reason for developing cell therapy treatments for cancer. Hiscox clearly has immense respect… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Clinical trials #Comment #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

From the editor: Staying focused

The drug discovery sector is amazing, says Lu Rahman. And while we have witnessed that on a global scale throughout the pandemic, we should also recognise some of the equally-outstanding non-Covid related developments that have recently taken place. There is, in my opinion, no better industry to be part of at the… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Bioinformatics #Biomedical research #Neurodegenerative disorders #Neuroscience #Research

Novel research identifies gene targets of stress hormones in the brain

New research has moved a step forward in understanding how glucocorticoid hormones (‘stress hormones’) act upon the brain and what their function is. The findings could lead to more effective strategies in the prevention and treatment of mental health disorders. The study, led by academics at the University of Bristol… Read More

#News #Trending News

#Assays #Biotherapeutics #C elegans #Drug development #Drug discovery #Therapeutics #Viosciences

Unlocking the microbiome as a target for drug discovery using C. elegans

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Biomedicine #Collaboration #Life sciences #Pharma

Stop, collaborate and listen: podcast

This is the latest episode of the free DDW podcast, “Stop, collaborate and listen: a model for successful pharma and vendor engagement”. It covers a narrated article written for DDW and read aloud by Megan Thomas. Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities… Read More

#Editor's Choice #News